Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report

BACKGROUND: Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) developed for treatment of patients with chronic myeloid leukemia (CML). The drug has been shown to act as a potent multikinase inhibitor by blocking not only the BCR-ABL1 gene sequence but also the SRC kinase family, thoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshima, Naoki, Mishima, Yoshiyuki, Shibagaki, Kotaro, Kawashima, Kousaku, Ishimura, Norihisa, Ikejiri, Fumiyoshi, Onishi, Chie, Okada, Takahiro, Inoue, Masaya, Moriyama, Ichiro, Suzumiya, Junji, Kinoshita, Yoshikazu, Ishihara, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789270/
https://www.ncbi.nlm.nih.gov/pubmed/33407162
http://dx.doi.org/10.1186/s12876-020-01584-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789270/
https://www.ncbi.nlm.nih.gov/pubmed/33407162
http://dx.doi.org/10.1186/s12876-020-01584-6

Ejemplares similares